Research programme: human plasma-derived biologics - Abeona Therapeutics

Drug Profile

Research programme: human plasma-derived biologics - Abeona Therapeutics

Alternative Names: A1PI - Abeona Therapeutics; AAT - Abeona Therapeutics; AHF - Abeona Therapeutics; Alpha-1 protease inhibitor - Abeona Therapeutics; Antihaemophilic factor VIII - Abeona Therapeutics; Coagulation factors - Abeona Therapeutics; Human plasma-derived therapeutics - Abeona Therapeutics; IVIG - Abeona Therapeutics; Protein biologic therapeutics - Abeona Therapeutics; PTB-101 SDF Alpha™; PTB-201 SDF IVIG™; SDF Alpha™; SDF Gamma™

Latest Information Update: 15 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PlasmaTech Biopharmaceuticals
  • Developer Abeona Therapeutics
  • Class Acute-phase proteins; Alpha globulins; Blood coagulation factors; Blood proteins; Enzymes; Glycoproteins; Immunoglobulins; Immunoproteins; Secretory proteinase inhibitory proteins; Serum globulins
  • Mechanism of Action Alpha 1-antitrypsin replacements; Factor VIII stimulants; Immunoglobulin stimulants; Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Chronic obstructive pulmonary disease; Immunocompromised infections
  • Research Alpha 1-antitrypsin deficiency; Blood coagulation disorders; Haemophilia A

Most Recent Events

  • 01 Jan 2015 PlasmaTech Biopharmaceuticals amends a licence agreement covering Salt Diafiltration (SDF™) Process technology obtained from Plasma Technologies
  • 31 Dec 2014 PlasmaTech Biopharmaceuticals has patent protection for Salt Diafiltration Process technology (SDF™) in USA, Europe, China and Australia (PlasmaTech Biopharmaceuticals 10-K, March 2015)
  • 31 Dec 2014 PlasmaTech Biopharmaceuticals has patents pending for Salt Diafiltration Process technology (SDF™) in Canada and India (PlasmaTech Biopharmaceuticals 10-K, March 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top